We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,640.50 | 1,640.00 | 1,641.00 | 1,647.00 | 1,635.00 | 1,638.50 | 514,837 | 10:32:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.72 | 67.6B |
From Apr 2019 to Apr 2024
LONDON, July 29, 2015 /PRNewswire/ --
Commenting on GSK's Q2 performance, the first since the Novartis transaction closed, CFO Simon Dingemans reveals sales rose during the period and that newly acquired businesses are performing in line with expectations. Ahead of a November R&D update day he reiterates the company's commitment to sustainable innovation.
The interview and transcript are available now on http://video.merchantcantos.com
MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@merchantcantos.com or phone +44-(0)207-936-1352.
SOURCE GlaxoSmithKline
Copyright 2015 PR Newswire
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
